Influence of selegiline on dopaminergic neurons in patients with early Parkinson disease

Chinese Journal of Clinical Rehabilitation

Volumn 9, Issue 9, 2005, Pages 190-192

  Zhao, Wu Wei ^a   He, Xiao Jun ^a   Zhang, Zhi Feng ^b   Kong, Ling Shan ^b   Su, Jing Jing ^b   Xie, Hui Jun ^b  

^a No 81 Hospital of PLA   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; PLACEBO; SELEGILINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOPAMINERGIC NERVE CELL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; MALE; NAUSEA; OUTCOMES RESEARCH; PARKINSON DISEASE; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; STRIATE CORTEX; TREATMENT OUTCOME; XEROSTOMIA;

EID: 20444460769     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Reichmann H. Neuroprotection in Parkinson disease. J Neurol 2002;249:21-3
2. Stocchi F, Olanow CW. Neuroprotection in Parkinson disease: clinical trials. J Ann Neurol 2003;53(Suppl3):87-97
3. Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson disease. J Ann Neurol 2003;53:110-9
4. 123I]β-CIT SPECT. J Neural Transm 2000;107:543-52
5. 123I]β-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson disease. J Neural Transm 2001;108:1011-9
6. Saji H, Iida Y. Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography(PET) and single photon emission computed tomography(SPECT). J Nippon Yakurigaku Zasshi 2003;121(3): 181-91
7. Saji H, Iida Y, Kawashima H, et al. In vivo imaging of brain dopaminergic neurotransmission system in small animals with high-resolution single photon emission computed tomography. J Anal Sci 2003;19(1):67-71
8. 123I] β-CIT and SPECT. J Cere Blood Flow Metab 1995;15(suppl 1):37
9. Clarke CE. A "cure" for Parkinson disease: can neuroprotection be proven with current trial designs? J Mov Disord 2004;19(5):491-8
10. Ebadi M, Sharma S, Shavali S, et al. Neuroprotective actions of selegiline. J Neurosci Res 2002;67:285-9
11. Olanow CW, Hauser RA, Gauger L. The effect of deprenyl and levodopa on the progression of Parkinson disease. J Ann Neurol 1995;38(5):771-7
12. The Parkinson Study Group. Mortality in DATATOP: a multicenger trial in early stage Parkinson disease. J Ann Neurol 1998;43:318-25
13. Neurotti A, Bizzarri G, Calzetti S. Long-term persistence of symptomatic effect of selegiline in Parkinson diseases. A two-month Placebo-controlled withdrawal study. J Neural Transm 2001; 108:215-9